92 related articles for article (PubMed ID: 22084895)
1. Persistence with biologic therapies in the Medicare coverage gap.
Tamariz L; Uribe CL; Luo J; Hanna JW; Ball DE; Krohn K; Meadows ES
Am J Manag Care; 2011 Nov; 17(11):753-9. PubMed ID: 22084895
[TBL] [Abstract][Full Text] [Related]
2. Out-of-pocket drug costs and drug utilization patterns of postmenopausal Medicare beneficiaries with osteoporosis.
Conwell LJ; Esposito D; Garavaglia S; Meadows ES; Colby M; Herrera V; Goldfarb S; Ball D; Marciniak M
Am J Geriatr Pharmacother; 2011 Aug; 9(4):241-9. PubMed ID: 21616722
[TBL] [Abstract][Full Text] [Related]
3. Etanercept and adalimumab treatment patterns in psoriatic arthritis patients enrolled in a commercial health plan.
Chastek B; Fox KM; Watson C; Gandra SR
Adv Ther; 2012 Aug; 29(8):691-7. PubMed ID: 22903239
[TBL] [Abstract][Full Text] [Related]
4. Impact of cost sharing on prescription drugs used by Medicare beneficiaries.
Goedken AM; Urmie JM; Farris KB; Doucette WR
Res Social Adm Pharm; 2010 Jun; 6(2):100-9. PubMed ID: 20511109
[TBL] [Abstract][Full Text] [Related]
5. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.
DeWitt EM; Glick HA; Albert DA; Joffe MM; Wolfe F
Arch Intern Med; 2006 Jan; 166(1):57-63. PubMed ID: 16401811
[TBL] [Abstract][Full Text] [Related]
6. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
Carter CT; Changolkar AK; Scott McKenzie R
J Med Econ; 2012; 15(2):332-9. PubMed ID: 22168788
[TBL] [Abstract][Full Text] [Related]
8. PDP or MA-PD? Medicare part D enrollment decisions in CMS Region 25.
Cline RR; Worley MM; Schondelmeyer SW; Schommer JC; Larson TA; Uden DL; Hadsall RS
Res Social Adm Pharm; 2010 Jun; 6(2):130-42. PubMed ID: 20511112
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.
Bonafede M; Fox KM; Watson C; Princic N; Gandra SR
Adv Ther; 2012 Aug; 29(8):664-74. PubMed ID: 22886712
[TBL] [Abstract][Full Text] [Related]
10. Part D plan enrollment by uninsured medicare beneficiaries.
Maciejewski ML; Farley JF; Hansen RA; Wei D; Harman JS
Med Care; 2010 Feb; 48(2):183-6. PubMed ID: 20057332
[TBL] [Abstract][Full Text] [Related]
11. Comparing pre-gap and gap behaviors for Medicare beneficiaries in a Medicare managed care plan.
Nair KV; Frech-Tamas F; Jan S; Wolfe P; Allen RR; Saseen JJ
J Health Care Finance; 2011; 38(2):38-53. PubMed ID: 22372031
[TBL] [Abstract][Full Text] [Related]
12. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
13. Effect of the Medicare Part D coverage gap on medication use among patients with hypertension and hyperlipidemia.
Li P; McElligott S; Bergquist H; Schwartz JS; Doshi JA
Ann Intern Med; 2012 Jun; 156(11):776-84, W-263, W-264, W-265, W-266, W-267, W-268, W-269. PubMed ID: 22665815
[TBL] [Abstract][Full Text] [Related]
14. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population.
Ollendorf DA; Klingman D; Hazard E; Ray S
Clin Ther; 2009 Apr; 31(4):825-35. PubMed ID: 19446156
[TBL] [Abstract][Full Text] [Related]
15. Part D coverage gap and adherence to diabetes medications.
Gu Q; Zeng F; Patel BV; Tripoli LC
Am J Manag Care; 2010; 16(12):911-8. PubMed ID: 21348561
[TBL] [Abstract][Full Text] [Related]
16. The use of disease-modifying agents among multiple sclerosis patients enrolled in medicare from 1995 to 2002 and the impact of medicare part D: analysis of claims data from the medicare current beneficiary survey.
Lundy J; Craig BM
Clin Ther; 2006 Jan; 28(1):140-5. PubMed ID: 16490588
[TBL] [Abstract][Full Text] [Related]
17. Insurance coverage and health care use among near-elderly women.
Xu X; Patel DA; Vahratian A; Ransom SB
Womens Health Issues; 2006; 16(3):139-48. PubMed ID: 16765290
[TBL] [Abstract][Full Text] [Related]
18. Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.
Polinski JM; Mohr PE; Johnson L
Arthritis Rheum; 2009 Jun; 61(6):745-54. PubMed ID: 19479704
[TBL] [Abstract][Full Text] [Related]
19. Cost per treated patient for etanercept, adalimumab, and infliximab across adult indications: a claims analysis.
Bonafede MM; Gandra SR; Watson C; Princic N; Fox KM
Adv Ther; 2012 Mar; 29(3):234-48. PubMed ID: 22411424
[TBL] [Abstract][Full Text] [Related]
20. Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.
Wailoo AJ; Bansback N; Brennan A; Michaud K; Nixon RM; Wolfe F
Arthritis Rheum; 2008 Apr; 58(4):939-46. PubMed ID: 18383356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]